|
Provectus Pharmaceuticals |
|
|
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA
phone:(866) 594-5999
fax:(866) 998-0005
|
|
| Symbol |
PVCT |
| Exchange |
OBB |
| Founded |
2002 |
| Employees |
4 |
|
|
| www.pvct.com/
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Provectus technologies is developing a novel drug that selectively targets and destroys cancer cells without harming surrounding healthy tissue |
|
| Management |
| Craig Dees Ph.D., Chief Executive Officer; Timothy Scott Ph.D., President; Eric Wachter Ph.D., Executive Vice President; Peter R. Culpepper CPA, MBA, Chief Financial Officer, Chief Operating Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| chemoablation, metastatic, melanoma, intralesional, rose bengal, oncology, cancer |
|
|
|
| Description |
|
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver. The Company has received orphan drug designation from the FDA for its melanoma indication. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed its Phase 2 trials of PV-10 as a therapy for metastatic melanoma. |
|
| Products / Services |
Metastatic Melanoma (PV-10);
Atopic Dermatitis (PH-10);
Psoriasis (PH-10);
Breast Cancer (PV-10);
Liver Cancer (PV-10)
|
|
|
| Status |
- Held end-of-Phase 2 meeting and discussion about the design of a pivotal Phase 3 randomized control study of PV-10 with the FDA
- End-of-Phase 2 meeting was held with the Australian Therapeutic Goods Administration (TGA) to discuss path to approval
- Completed Phase 2 trial of Atopic Dermatitis (PH-10)
- Completed Phase 2 trial of Psoriasis (PH-10)
- Initiated Phase 2C trial of Psoriasis (PH-10)
- Phase 1 safety and efficacy trial on 15 patients with recurrent breast cancer completed.
- Phase 1 completed Lover Cancer (PV-10) |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
